Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 14/20 | 0.46 |
| ▸ | METAP1 | P53582 | 10/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13427296 | 1.00 | METAP2 (0.46) | METAP2METAP1ANPEPDNPEPMMP1 | |
| Hydrochloric Acid SCHEMBL14973924 | 0.89 | METAP2 (0.46) | METAP2METAP1ANPEPDNPEPDPP8 | |
| SCHEMBL14974240 | 0.85 | METAP2 (0.48) | METAP2METAP1ANPEPDNPEPDPP8 | |
| Hydrochloric Acid SCHEMBL14973999 | 0.84 | METAP2 (0.41) | METAP2METAP1ANPEPDNPEPDPP8 | |
| SCHEMBL12207960 | 0.82 | METAP2 (0.41) | METAP2METAP1ANPEPDNPEPMMP1 | |
| SCHEMBL418571 | 0.82 | METAP2 (0.46) | METAP2METAP1ANPEPDNPEPDPP8 | |
| Hydrochloric Acid SCHEMBL7359557 | 0.81 | METAP2 (0.65) | METAP2METAP1 | |
| SCHEMBL15087464 | 0.77 | MMP1 (0.38) | METAP2MMP1MMP2MMP3PKM | |
| SCHEMBL12413226 | 0.77 | METAP2 (0.42) | METAP2METAP1ANPEPDNPEPDPP8 | |
| SCHEMBL8138370 | 0.77 | METAP2 (0.42) | METAP2METAP1ANPEPDNPEPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | METAP2 230/4885METAP1 100/4885ANPEP 27/4885 |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | METAP2 230/4885METAP1 100/4885ANPEP 27/4885 |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | METAP2 230/4885METAP1 100/4885ANPEP 27/4885 |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PEPD, PREP | METAP2 172/4885METAP1 89/4885ANPEP 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.